Jason M. Broderick is a journalist at various esteemed publications, including Diagnostic Imaging® and Cancer Network. He specializes in medicine and healthcare, focusing on critical topics such as oncology, immunotherapy, and pancreatic cancer research, while also covering hematology, endocrinology, and palliative care. Jason's work has been featured in multiple outlets, including CURE Media Group and Urology Times, showcasing his commitment to advancing knowledge in medical specialties and alternative medicine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jason M. Broderick's coverage predominantly revolves around healthcare and pharmaceutical topics, with a particular focus on scientific research and data-driven insights in the medical field. His articles often cite specific data, indicating an emphasis on evidence-based reporting.
Given his engagement with scientific findings and healthcare advancements, he is likely to be interested in pitches that offer access to new clinical studies, innovative medical technologies, or expert commentary from professionals involved in cutting-edge research within the specified medical domains. Pitches centered around breakthroughs related to bladder cancer treatment modalities, biomarker discoveries, urine testing innovations, or cancer diagnosis methodologies could align well with his coverage interests.
As Jason’s geographic focus is not specified but the content of his articles indicates a broad international perspective focused on developments across various regions without restriction to any specific location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jason M. Broderick
Systemic responses were observed across both Alpha DaRT-treated and untreated lesions per RECIST v1.1, supporting a potential abscopal/immune-amplifying interaction with PD-1 blockade. Median OS 18.2 months and PFS 5.4 months compared favorably with KEYNOTE-048 pembrolizumab monotherapy historical outcomes, acknowledging substantial cross-trial design and population differences.
By: Jason M. Broderick, Sabrina Serani
FDA accepted an NDA for daraxonrasib in previously treated metastatic PDAC, supported by RASolute 302 and prior breakthrough therapy and orphan drug designations. Phase 3 RASolute 302 showed OS nearly doubled versus chemotherapy in RAS G12 tumors (13.2 vs 6.6 months; HR 0.40) and was consistent in the overall population.
By: Jason M. Broderick
CLARITY-Gastric01 met dual OS primary end points, showing statistically significant, clinically meaningful benefit for Sone‑Ve over chemotherapy in third-line+ and overall second-line+ cohorts. Blinded independent central review demonstrated only a PFS improvement trend in second-line+ disease, failing to reach statistical significance despite OS gains.
By: Jason M. Broderick, Sabrina Serani
Priority review positions subcutaneous amivantamab as a potential first-in-class EGFR/MET-targeted option after platinum and PD-1/PD-L1 failure in HPV-unrelated R/M HNSCC. Blinded central review showed 42% ORR with 15% CR; 56% of responses persisted ≥6 months and 63% were ongoing at analysis.
By: Jason M. Broderick
"Although I am disappointed that the PFS improvement was not statistically significant, I look forward to continuing to follow these results," Robert Coleman, MD.
By: Jason M. Broderick
KEYNOTE-689 demonstrated superior EFS with neoadjuvant plus adjuvant pembrolizumab (median 51.8 vs 30.4 months; HR 0.73), establishing clinical benefit for perioperative immunotherapy in resectable HNSCC. Partitioned survival modeling estimated CPS >10 gains of ~1.35 QALYs at ~$181,900 incremental cost, producing an ICER of ~$134,700, consistent with US $150,000 willingness-to-pay benchmarks.
By: Jason M. Broderick
ERAS-0015 is being tested in AURORAS-1, an open-label study enrolling patients with RAS-mutant solid tumors.
By: Jason M. Broderick
A large US data set from 5,497 clinical sites demonstrated significant reductions in overall CGP turnaround time between 2018 and 2024, with NSCLC samples consistently fastest. Pronounced site-to-site variability persisted, with the slowest quintile showing nearly 2-fold longer turnaround time than the fastest across tumor types and within NSCLC.
By: Jason M. Broderick
The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.
Scaling back thyroid ultrasonography referrals may meaningfully reduce diagnoses without affecting survival.
